OBI Stock Overview
A life-sciences company, engages in the development and commercialization of antimicrobial therapies in Canada and internationally.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Ondine Biomedical Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | UK£0.087 |
52 Week High | UK£0.12 |
52 Week Low | UK£0.05 |
Beta | 0.10 |
11 Month Change | 37.25% |
3 Month Change | 11.11% |
1 Year Change | -22.22% |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -84.91% |
Recent News & Updates
Shareholder Returns
OBI | GB Medical Equipment | GB Market | |
---|---|---|---|
7D | -2.8% | -8.3% | -1.2% |
1Y | -22.2% | -1.7% | 8.9% |
Return vs Industry: OBI underperformed the UK Medical Equipment industry which returned -1.7% over the past year.
Return vs Market: OBI underperformed the UK Market which returned 8.9% over the past year.
Price Volatility
OBI volatility | |
---|---|
OBI Average Weekly Movement | 10.1% |
Medical Equipment Industry Average Movement | 5.6% |
Market Average Movement | 4.7% |
10% most volatile stocks in GB Market | 9.6% |
10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: OBI's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: OBI's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1996 | n/a | Carolyn Cross | ondinebio.com |
Ondine Biomedical Inc., a life-sciences company, engages in the development and commercialization of antimicrobial therapies in Canada and internationally. Its product platform is Photodisinfection, a light-based antimicrobial technology that provides destruction of pathogens without causing antibiotic resistance. The company’s lead product is Steriwave, a nasal photodisinfection solutions that destroys bacteria, viruses, and fungi colonizing the nose which leads to healthcare-associated infections.
Ondine Biomedical Inc. Fundamentals Summary
OBI fundamental statistics | |
---|---|
Market cap | UK£24.26m |
Earnings (TTM) | -UK£7.92m |
Revenue (TTM) | UK£906.45k |
26.8x
P/S Ratio-3.1x
P/E RatioIs OBI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
OBI income statement (TTM) | |
---|---|
Revenue | CA$1.63m |
Cost of Revenue | CA$653.00k |
Gross Profit | CA$981.00k |
Other Expenses | CA$15.26m |
Earnings | -CA$14.27m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.051 |
Gross Margin | 60.04% |
Net Profit Margin | -873.56% |
Debt/Equity Ratio | 0% |
How did OBI perform over the long term?
See historical performance and comparison